Source comparison
Tesamorelin's GHRH Receptor Pathway vs Ghrelin Mimetics
Tesamorelin functions as a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH), binding to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland. When tesamorelin binds to GHRHR, it activates adenylyl cyclase t
This comparison does not assign a generated winner or score.
- Tesamorelin functions as a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH), binding to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland. When tesamorelin binds to GHRHR, it activates adenylyl cyclase through G-protein coupling, increasing intracellular cyclic AMP (cAMP) levels. This triggers calcium channel opening and vesicular release of stored growth hormone into systemic circulation. The critical feature of this pathway: it preserves physiologic regulation. IGF-1 produced in the liver in response to GH feeds back to the hypothalamus and pituitary, suppressing further GHRH secretion and GH release when levels are sufficient.
- Ghrelin mimetics. GHRP-2, GHRP-6, ipamorelin, hexarelin. Take a different route entirely. These peptides bind to the growth hormone secretagogue receptor (GHS-R1a), also called the ghrelin receptor, which is expressed not only in the pituitary but throughout the hypothalamus, gastrointestinal tract, and cardiovascular system. GHS-R activation stimulates GH release through intracellular calcium mobilization and protein kinase C activation, independent of GHRH signaling. This means ghrelin mimetics can trigger GH pulses even when IGF-1 levels are elevated. The feedback loop that normally regulates endogenous GH secretion doesn't suppress secretagogue-induced release to the same degree.
- The downstream consequence: GHRH analogs like tesamorelin produce GH secretion patterns that closely mimic natural physiology. Circadian variation intact, pulsatile release maintained, and self-limiting response tied to metabolic demand. Ghrelin mimetics produce supraphysiologic GH spikes that don't taper off as cleanly, which is why they're often cycled in research protocols to prevent receptor desensitization. Our team has reviewed pharmacokinetic data from both classes. Tesamorelin's half-life of 26–38 minutes supports once-daily subcutaneous administration with predictable trough and peak GH levels, while shorter-acting secretagogues like ipamorelin (half-life ~2 hours) are typically dosed multiple times per day to sustain GH elevation.